The incidence and prevalence of heart failure with preserved ejection fraction (HFpEF)
continue to rise in tandem with the increasing age and burdens of obesity, sedentariness …

Heart failure (HF) is a progressive disease characterized by variable durations of
symptomatic stability often punctuated by episodes of worsening despite continued therapy …

Background Device-detected atrial high-rate episodes (AHREs) are atrial arrhythmias
detected by implanted cardiac devices. AHREs resemble atrial fibrillation but are rare and …

Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of
hospitalization for heart failure and cardiovascular death among patients with chronic heart …

Abstract Aims The Valve Academic Research Consortium (VARC), founded in 2010, was
intended to (i) identify appropriate clinical endpoints and (ii) standardize definitions of these …

Aims Sodium–glucose co‐transporter 2 (SGLT2) inhibitors, originally developed as glucose‐
lowering agents, have been shown to reduce heart failure hospitalizations in patients with …

Background Interest in the application of machine learning (ML) to the design, conduct, and
analysis of clinical trials has grown, but the evidence base for such applications has not …

Background Data are lacking on the comparative effectiveness of commonly used glucose-
lowering medications, when added to metformin, with respect to microvascular and …

Deep learning (DL)-based predictive models from electronic health records (EHRs) deliver
impressive performance in many clinical tasks. Large training cohorts, however, are often …

Background: Empagliflozin reduces the risk of cardiovascular death or hospitalization for
heart failure in patients with heart failure and a reduced ejection fraction, with or without …